Clinical Trials Browser

Carcinoma, Transitional Cell

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Neuroendocrine Tumors

Hemangiosarcoma

Hodgkin Disease

Fallopian Tube Neoplasms, Ovarian Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Salivary Gland Neoplasms, Thyroid Neoplasms

Brain Neoplasms

Squamous Cell Carcinoma of Head and Neck

Anus Neoplasms

HER2-negative Breast Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Dysplasia

Carcinoma, Renal Cell

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

Carcinoma, Non-Small-Cell Lung, Recurrence

Breast Neoplasms, Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Glioblastoma

Ovarian Neoplasms

Colorectal Neoplasms, Microsatellite Instability

Squamous Cell Carcinoma of Head and Neck

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Muscle Invasive Bladder Urothelial Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Colonic Neoplasms

Carcinoma, Squamous Cell

Thyroid Carcinoma, Anaplastic

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell

Lung Diseases, Interstitial

Carcinoma, Merkel Cell

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Clinical Trials

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

TOP 1501

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

I-SPY

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

iPRIME

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

PRELUDE

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

TELESCOPE

NeoSenti

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

ARETHUSA

KIEO

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

PRELUDE

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

RESET C2

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Neo IRENIE

IMPROEV

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

MCC

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer